Intellectual Property and Open Movements (IP&OM)

Issues and developments related to Intellectual Property (e.g. Copyright, Fair Use, Patents, Trademarks, Trade Secrets) and Open Movements (e.g. Open Access, Open Data, Open Educational Resources (OER)), examined in the "Intellectual Property and Open Movements" and "Ethics of Data, Information, and Emerging Technologies" graduate courses I teach at the University of Pittsburgh School of Computing and Information. -- Kip Currier, PhD, JD

Showing posts with label Gilead Sciences Inc.. Show all posts

Thursday, November 7, 2019

Trump administration sues drugmaker Gilead Sciences over patent on Truvada for HIV prevention; The Washington Post, November 7, 2019

Christopher Rowland, The Washington Post; Trump administration sues drugmaker Gilead Sciences over patent on Truvada for HIV prevention

"The Trump administration took the rare step Wednesday of filing a patent infringement lawsuit against pharmaceutical manufacturer Gilead Sciences over sales of Truvada for HIV prevention, a crucial therapy invented and patented by Centers for Disease Control researchers."

Saturday, March 26, 2016

Reuters; Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute; Reuters, 3/24/16

Reuters; Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute:

"A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.
The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015."